Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 8 November 2024, 20:23 HKT/SGT
Share:
ITC's Final Decision Confirms Innoscience's Customers Remain Unaffected by the Innoscience-EPC Patent Row
- Finds No Infringement of the '508 Patent
- and Paves the Way for Designing Around the Remaining '294 Patent Currently Stands Challenged as Invalid at USPTO

HONG KONG, Nov 8, 2024 - (ACN Newswire) - Innoscience Technology, a company founded to create a global energy ecosystem based on high-performance, low-cost, gallium-nitride-on-silicon (GaN-on-Si) power solutions, announced today that the U.S. International Trade Commission’s (“ITC”) November 7, 2024 final determination has confirmed the ability of Innoscience’s customers to import their products into U.S. remain unaffected by the ongoing patent dispute between Innoscience and Efficient Power Conversion Corporation (“EPC”).

In May last year, EPC launched a lawsuit against Innoscience at the ITC, falsely alleging infringement of EPC’s ’508 and ’294 patents. Following an administrative law judge’s initial determination in the past July finding no infringement of claim 1 (the only asserted claim) of the ’508 patent, the latest ITC final determination once again affirmed no violation as to this patent—a huge success for Innoscience.

The final determination, however, affirmed the part of the judge’s initial determination that found violation as to claims 2 and 3 the ’294 patent. The ITC hence has determined to issue a limited exclusion order prohibiting importation of certain accused Innoscience chips. Innoscience disagrees with and will appeal this ruling. This is at least because the ‘294 patent is invalid. Indeed, the U.S Patent and Trademark Office (“USPTO”) instituted an inter partes review (“IPR”) challenging all claims of the ’294 patent under four different grounds and has agreed with Innoscience’s invalidity arguments. The ’294 IPR decision will issue in March 2025.

Innoscience also notes it is established U.S. law that the limited exclusion order does not prohibit Innoscience’s customers from importing end products that use the accused chips. Moreover, since the final decision clarified the meaning of the claim term “compensated GaN layer,” which is at the center of the dispute surrounding the ’294 patent, it has provided clear guidance for Innoscience to design around the ’294 patent by avoiding use of the “compensated GaN layer.” Innoscience already has the design around in place and will release the new products soon.  

Accordingly, the EPC litigation shall have no impact on Innoscience’s customers. Moreover, Innoscience will continue to solve the dispute with EPC through appeals in court and invalidity challenges at the USPTO, and is confident that it will achieve a final complete victory. 




Topic: Press release summary Sectors: Electronics
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Military Metals Announces Appointment of Mark Saxon to Its Board of Directors  
Nov 8, 2024 23:58 HKT/SGT
ITC's Final Decision Confirms Innoscience's Customers Remain Unaffected by the Innoscience-EPC Patent Row  
Nov 8, 2024 20:23 HKT/SGT
The 32nd Hong Kong International Optical Fair attracts some 13,000 buyers  
Nov 8, 2024 20:10 HKT/SGT
Dynasty Wins One Silver and One Bronze Medals at 2024 HKIWSC  
Nov 8, 2024 19:32 HKT/SGT
Hong Kong Fashion Designers Association Celebrates 40th Anniversary  
Nov 8, 2024 17:56 HKT/SGT
Three Ways AI Tools Can Help Drive Efficiencies for Small Businesses  
Nov 8, 2024 16:00 HKT/SGT
TRIO Launches 360 Botslab's Smart Home Security Products in Malaysia, Introducing Advanced AI Solutions to Local Consumers  
Nov 8, 2024 14:00 HKT/SGT
International Symposium 'Creating the Future' Sparks Discussions on Technology, Society, and Future Civilization  
Nov 8, 2024 14:00 HKT/SGT
ArborChat Outperforms the Market by 750 Basis Points Over a Year  
Nov 8, 2024 10:49 HKT/SGT
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024  
Friday, November 8, 2024 9:31:00 AM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: